{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-297683","form_type":"8-K","ticker":null,"cik":"0001293971","company_name":"bluebird bio, Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.551025+00:00","generated_at":"2026-06-07T11:13:04.101981+00:00","sec_items":["1.01","2.03","5.03","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"bluebird bio enters $100M accounts receivable factoring agreement to accelerate cash collection","bullets":["Up to $100M revolving factoring facility, 90% advance rate on receivables for LYFGENIA, ZYNTEGLO, SKYSONA.","Fee: prime rate + 1.35% on funded amount plus 0.05% collateral monitoring fee; proceeds for working capital.","12-month initial term, renewable annually; early termination fee 2% (first year) or 0.75% thereafter.","Purchaser assumes credit risk; seller must repurchase ineligible or disputed accounts.","Bylaws amended to adopt universal proxy rules and enhance disclosure for stockholder nominations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-297683","json":"https://secwatch.observer/filing/0001193125-23-297683.json","markdown":"https://secwatch.observer/filing/0001193125-23-297683.md","text":"https://secwatch.observer/filing/0001193125-23-297683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523297683/0001193125-23-297683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523297683/d632206d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:13:04.101981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"132318d22076a42fed30fa13ed46ff9b8c87dd4f","claim":"bluebird bio, Inc. incurred debt of up to $100,000,000.00 with Alterna Capital Solutions LLC at prime rate plus 1.35% maturing 12 months.","evidence_excerpt":"The factoring facility provides for the Company to have access to up to $100,000,000.00 (the “Maximum Credit”) on a revolving basis","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523297683/0001193125-23-297683-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Principal","value":"up to $100,000,000.00"},{"label":"Counterparty","value":"Alterna Capital Solutions LLC"},{"label":"Rate","value":"prime rate plus 1.35%"},{"label":"Maturity","value":"12 months"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"3caa8b0136f6148db0bc40023e78f54d37697429","claim":"bluebird bio, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination and proposal procedures, require proxy card color other than white, delete obsolete provisions, and make technical changes (effective 2023-12-14).","evidence_excerpt":"On December 14, 2023, the Board of Directors (the “Board”) of the Company approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523297683/0001193125-23-297683-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-12-14"}],"fact_type":"governance_change"},{"claim_id":"c525e66917b2d29752f3cb8d50e4490b923adf4b","claim":"bluebird bio, Inc. entered into Agreement with Alterna Capital Solutions LLC valued at $100,000,000.00 (effective 2023-12-14).","evidence_excerpt":"On December 14, 2023, bluebird bio, Inc. (the “Company”) entered into an accounts receivable factoring agreement (the “Agreement”) with Alterna Capital Solutions LLC (the “Buyer”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293971/000119312523297683/0001193125-23-297683-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Alterna Capital Solutions LLC"},{"label":"Value","value":"$100,000,000.00"},{"label":"Effective","value":"2023-12-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}